IP Library Granted Patent US 9,765,381
Granted Patent B2
US 9,765,381 · App. 15/379,981 · Granted Sep 19, 2017

Mutated genes for the catalytic protein of oplophorus luciferase and use thereof

Inventors: Satoshi Inouye (Kanagawa, JP); Junichi Sato (Kanagawa, JP)
Assignee: JNC CORPORATION
C12Q1/66C12N9/0069C12Y113/12007
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,765,381
App. No.
15/379,981
Granted
Sep 19, 2017
Kind
B2
Abstract

Secreted luciferases which are different from those known heretofore have been desired. The present invention provides a luciferase mutant comprising an amino acid sequence in which at least one amino acid selected from amino acids at the positions of 1 to 4 is deleted in the amino acid sequence of SEQ ID NO: 2.

Claims (12)

1. A method for assaying the transcription activity of a promoter-containing polynucleotide sequence, which comprises using a polynucleotide encoding a luciferase mutant as a reporter gene, wherein the polynucleotide encoding the luciferase mutant is operably fused to the promoter-containing polynucleotide sequence, wherein the luciferase mutant expressed is contacted with a luciferin, and wherein the luciferase mutant is selected from (a) to (e) below:

(a) a luciferase mutant consisting of an amino acid sequence in which at least one amino acid selected from amino acids at the positions of 1 to 4 is deleted in the amino acid sequence of SEQ ID NO: 2;

(b) a luciferase mutant consisting of an amino acid sequence in which at least one amino acid selected from amino acids at the positions of 1 to 4 is deleted in the amino acid sequence of SEQ ID NO: 2 and an amino acid sequence excluding the amino acids at the positions of 1 to 4 is an amino acid sequence in which 1 to 17 amino acids are deleted, substituted, inserted and/or added in the amino acid sequence at the positions of 5 to 169 of SEQ ID NO: 2, and having a luciferase activity;

(c) a luciferase mutant consisting of an amino acid sequence in which at least one amino acid selected from amino acids at the positions of 1 to 4 is deleted in the amino acid sequence of SEQ ID NO: 2 and an amino acid sequence excluding the amino acids at the positions of 1 to 4 has at least 90% identity to the amino acid sequence at the positions of 5 to 169 of SEQ ID NO: 2, and having a luciferase activity;

(d) a luciferase mutant consisting of an amino acid sequence in which at least one amino acid selected from amino acids at the positions of 1 to 4 is deleted in the amino acid sequence of SEQ ID NO: 2 and an amino acid sequence excluding the amino acids at the positions of 1 to 4 is encoded by a polynucleotide which hybridizes under high stringent conditions to a polynucleotide consisting of a nucleotide sequence complementary to a nucleotide sequence encoding the amino acid sequence at the positions of 5 to 169 of SEQ ID NO: 2, wherein the high stringent conditions are 5×SSC, 5×Denhart's solution, 0.5% (w/v) SDS, 50% (v/v) formamide and 50° C., and having a luciferase activity; and,

(e) a luciferase mutant consisting of an amino acid sequence selected from SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 and SEQ ID NO: 10.

2. The method according to claim 1 , wherein the luciferin is coelenterazines.

3. The method according to claim 2 , wherein the coelenterazines is bis-coelenterazine or 6h-f-coelenterazine.

4. The method according to claim 1 , wherein the luciferase mutants defined in (b) to (d) above are mutants defined in (b-1) to (d-1) below:

(b-1) a luciferase mutant consisting of an amino acid sequence in which at least one amino acid selected from amino acids at the positions of 1 to 4 is deleted in the amino acid sequence of SEQ ID NO: 2 and an amino acid sequence excluding the amino acids at the positions of 1 to 4 is an amino acid sequence in which 1 to 9 amino acids are deleted, substituted, inserted and/or added in the amino acid sequence at the positions of 5 to 169 of SEQ ID NO: 2, and having a luciferase activity;

(c-1) a luciferase mutant consisting of an amino acid sequence in which at least one amino acid selected from amino acids at the positions of 1 to 4 is deleted in the amino acid sequence of SEQ ID NO: 2 and an amino acid sequence excluding the amino acids at the positions of 1 to 4 has at least 95% identity to the amino acid sequence at the positions of 5 to 169 of SEQ ID NO: 2, and having a luciferase activity; and,

(d-1) a luciferase mutant consisting of an amino acid sequence in which at least one amino acid selected from amino acids at the positions of 1 to 4 is deleted in the amino acid sequence of SEQ ID NO: 2 and an amino acid sequence excluding the amino acids at the positions of 1 to 4 is encoded by a polynucleotide which hybridizes under high stringent conditions to a polynucleotide consisting of a nucleotide sequence complementary to a nucleotide sequence encoding the amino acid sequence at the positions of 5 to 169 of SEQ ID NO: 2, wherein the high stringent conditions are 5×SSC, 5×Denhart's solution, 0.5% (w/v) SDS, 50% (v/v) formamide and 50° C. and having a luciferase activity.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2023
From: JNC CORPORATION
To: PROLUME LTD.
Reel/Frame 063962/0872 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2016
From: INOUYE, SATOSHI; SATO, JUNICHI
To: JNC CORPORATION
Reel/Frame 040990/0376 →
Priority Claims (1)
JP 2013-268416 · Dec 26, 2013 · national
Continuity (4)
Division 15243033 · Aug 22, 2016
Division 15157930 · May 18, 2016
Division 14576366 · Dec 19, 2014
Related Publication 20170114388A1 · Apr 27, 2017